Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company has a licensing and co-development agreement with Amgen Inc. for AMG 714. The company was incorporated in 2016 and is based in Oldwick, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone908-336-0360
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees13
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Provention Bio (NASDAQ:PRVB) Frequently Asked Questions
What is Provention Bio's stock symbol?
Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."
How were Provention Bio's earnings last quarter?
Provention Bio Inc (NASDAQ:PRVB) issued its earnings results on Tuesday, August, 6th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.02. View Provention Bio's Earnings History.
When is Provention Bio's next earnings date?
What price target have analysts set for PRVB?
4 equities research analysts have issued 12-month price targets for Provention Bio's stock. Their forecasts range from $6.00 to $35.00. On average, they anticipate Provention Bio's share price to reach $20.25 in the next twelve months. This suggests a possible upside of 114.1% from the stock's current price. View Analyst Price Targets for Provention Bio.
What is the consensus analysts' recommendation for Provention Bio?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Provention Bio.
What are Wall Street analysts saying about Provention Bio stock?
Here are some recent quotes from research analysts about Provention Bio stock:
- 1. According to Zacks Investment Research, "Provention Bio, Inc. is a biopharmaceutical company. It focuses on development of novel therapeutics and solutions to intercept and prevent immune-mediated disease. The company's product pipeline consists of PRV-031, PRV-6527, PRV-300, PRV-3279 and PRV-101 which are in clinical stage. Provention Bio, Inc. is based in NJ, United States. " (5/16/2019)
- 2. HC Wainwright analysts commented, "We value Provention Bio using a discounted cash flow (DCF)-based methodology, which ascribes a 70% probability of approval to PRV-031, a 50% probability of approval to 40% probability of approval to PRV-300. We do not currently assign value to any of the company’s other assets." (1/29/2019)
Has Provention Bio been receiving favorable news coverage?
News headlines about PRVB stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Provention Bio earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Provention Bio.
Are investors shorting Provention Bio?
Provention Bio saw a increase in short interest in August. As of August 31st, there was short interest totalling 2,050,400 shares, an increase of 42.0% from the July 31st total of 1,444,400 shares. Based on an average daily volume of 988,400 shares, the days-to-cover ratio is presently 2.1 days. Approximately 7.9% of the company's shares are short sold. View Provention Bio's Current Options Chain.
Who are some of Provention Bio's key competitors?
Some companies that are related to Provention Bio include Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), G1 Therapeutics (GTHX), Turning Point Therapeutics (TPTX), Theravance Biopharma (TBPH), Radius Health (RDUS), Enanta Pharmaceuticals (ENTA), Opko Health (OPK), Gossamer Bio (GOSS), BELLUS Health (BLUSF), AnaptysBio (ANAB), Ra Pharmaceuticals (RARX), Innoviva (INVA), Spectrum Pharmaceuticals (SPPI) and Epizyme (EPZM).
What other stocks do shareholders of Provention Bio own?
Who are Provention Bio's key executives?
Provention Bio's management team includes the folowing people:
- Mr. Ashleigh Palmer B.Sc., M.B.A., Co-Founder, Pres, CEO & Director (Age 56)
- Mr. Francisco Leon M.D., Ph.D., Co-Founder, Chief Scientific Officer & Director (Age 47)
- Mr. Andrew T. Drechsler, Chief Financial Officer (Age 47)
- Dr. Eleanor L. Ramos, Chief Medical Officer & COO (Age 63)
- Mr. Cameron Gray Ph.D., MD & Director (Age 46)
Who are Provention Bio's major shareholders?
Provention Bio's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.23%), BlackRock Inc. (0.83%), Anson Funds Management LP (0.41%), Eversept Partners LP (0.19%), Sigma Planning Corp (0.16%) and Bailard Inc. (0.11%). Company insiders that own Provention Bio stock include Andrew T Drechsler, Anthony Digiandomenico, Ashleigh Palmer, Avery W Catlin, Francisco Leon, Peter A Appel and Wayne Pisano. View Institutional Ownership Trends for Provention Bio.
Which institutional investors are buying Provention Bio stock?
PRVB stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Anson Funds Management LP, Eversept Partners LP, Sigma Planning Corp, Bailard Inc., Northern Trust Corp and Susquehanna International Group LLP. Company insiders that have bought Provention Bio stock in the last two years include Andrew T Drechsler, Anthony Digiandomenico, Ashleigh Palmer, Avery W Catlin, Francisco Leon, Peter A Appel and Wayne Pisano. View Insider Buying and Selling for Provention Bio.
How do I buy shares of Provention Bio?
Shares of PRVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Provention Bio's stock price today?
One share of PRVB stock can currently be purchased for approximately $9.46.
How big of a company is Provention Bio?
Provention Bio has a market capitalization of $372.13 million. The company earns $-26,480,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Provention Bio employs 13 workers across the globe.View Additional Information About Provention Bio.
What is Provention Bio's official website?
How can I contact Provention Bio?
Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company can be reached via phone at 908-336-0360 or via email at [email protected]
MarketBeat Community Rating for Provention Bio (NASDAQ PRVB)
MarketBeat's community ratings are surveys of what our community members think about Provention Bio and other stocks. Vote "Outperform" if you believe PRVB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRVB will underperform the S&P 500 over the long term. You may vote once every thirty days.
